Introduction
In recent years, the conversation around weight management has changed dramatically. No longer is obesity seen simply as a matter of willpower or lifestyle alone — it is increasingly recognised as a chronic, relapsing disease influenced by biology, hormones, and genetics. With this shift has come an exciting development in medical treatment options: the arrival of highly effective injectable medications that harness the body’s own appetite-regulating hormones.
Two names dominate this space — Wegovy (semaglutide) and Mounjaro (tirzepatide). Both have generated headlines, celebrity endorsements, and huge patient demand. But what exactly are these medications? How do they differ? And most importantly, what do patients considering treatment need to know?
This article explores the science, clinical evidence, and patient experience of Wegovy and Mounjaro, offering clear guidance for anyone interested in medical weight management.
The Science Behind Wegovy and Mounjaro
At the heart of both medications is a class of hormones known as incretins. These are naturally released from the gut in response to food and play a vital role in regulating appetite, insulin release, and blood sugar levels.
- GLP-1 (Glucagon-like peptide-1): This hormone slows stomach emptying, increases satiety, and reduces appetite. It also improves insulin release after meals.
- GIP (Glucose-dependent insulinotropic polypeptide): Another incretin hormone that enhances insulin release and may complement GLP-1 in appetite regulation.
Wegovy (semaglutide) is a GLP-1 receptor agonist — meaning it mimics the action of GLP-1, helping patients feel fuller for longer and reducing calorie intake.
Mounjaro (tirzepatide) is unique because it is a dual GIP and GLP-1 receptor agonist. By activating both pathways, Mounjaro appears to produce greater effects on appetite control and weight loss than GLP-1 alone. This dual mechanism is what sets Mounjaro apart and why it is often described as the “next generation” of weight loss injections.
Clinical Evidence: What Do the Trials Show?
Both medications have been rigorously tested in large international clinical trials.
Wegovy – The STEP Trials
- In STEP-1 (published in New England Journal of Medicine, 2021), patients without diabetes lost an average of 14.9% of their body weight over 68 weeks.
- Many participants lost 15–20% of their body weight, with improvements in blood pressure, cholesterol, and quality of life.
- In patients with Type 2 diabetes, weight loss was slightly lower (around 10%), but still highly significant.
Mounjaro – The SURMOUNT-1 Trial
- Published in New England Journal of Medicine, 2022, this trial showed patients lost up to 21% of body weight at the highest dose (15 mg) over 72 weeks.
- Over half of patients on the 15 mg dose achieved at least 20% weight loss.
- Benefits also included improved blood sugar, reduced waist circumference, and better cardiovascular markers.
Head-to-head comparison: While there are no direct trials comparing Mounjaro and Wegovy in the same study, indirect comparisons suggest that Mounjaro generally produces greater weight loss than Wegovy, particularly at higher doses.
Dosing and Conversion
Wegovy is injected once a week and the dose is increased gradually:
- 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (maintenance dose).
Mounjaro follows a similar weekly injection schedule:
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (maintenance dose).
Because the drugs are different molecules with different mechanisms, they are not interchangeable on a milligram-for-milligram basis. However, approximate clinical equivalence can be described:
These comparisons are approximate and based on clinical outcomes rather than exact pharmacological equivalence. Any switch between medications should always be done under medical supervision.
Side Effects and Safety
Both Wegovy and Mounjaro share similar side effect profiles, mostly related to their effects on the digestive system:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal discomfort
These symptoms are usually temporary and improve as the body adjusts, especially if doses are increased slowly.
Rare but important risks include:
- Pancreatitis (inflammation of the pancreas).
- Gallbladder issues, such as gallstones.
- Very delayed gastric emptying, which can affect digestion.
Contraindications: Neither medication should be used in patients with a personal or family history of medullary thyroid cancer or MEN2 (Multiple Endocrine Neoplasia type 2).
Patient Experience: What Does It Feel Like?
Patients often describe a noticeable reduction in appetite, fewer food cravings, and the ability to eat smaller portions without feeling deprived.
Some report a sensation of “early fullness” — because both drugs slow gastric emptying, overeating can cause bloating or nausea. For this reason, patients are encouraged to eat slowly and stop when comfortably full.
Wegovy: Often praised for being predictable and widely studied, but some patients find weight loss plateaus at 10–15%.
Mounjaro: Many patients report stronger appetite suppression and more dramatic weight loss, but also a slightly higher chance of gastrointestinal side effects.
Transitioning Between Wegovy and Mounjaro
Sometimes patients may wish to switch from Wegovy to Mounjaro (or vice versa). This might be due to:
- Side effect tolerance.
- Availability and supply issues.
- Desire for greater efficacy.
Safe switching advice includes:
- Do not overlap the two medications.
- Switch at the time of the next scheduled injection.
- Start with a conservative equivalent dose and titrate upwards as tolerated.
- Close monitoring of weight, side effects, and blood tests is advised.
Long-Term Considerations
Obesity is a chronic condition, and evidence shows that stopping these medications often leads to weight regain. For this reason, both Wegovy and Mounjaro are generally considered long-term treatments.
However, this does not mean patients must rely solely on injections. When combined with lifestyle changes — nutrition, activity, sleep, and behavioural support — the results are stronger and more sustainable.
These medications should be seen as tools to support long-term weight and health, rather than quick fixes.
The Future of Weight Loss Medicine
The success of Wegovy and Mounjaro has sparked a wave of research into next-generation treatments. Drugs in development include:
- Retatrutide: A “triple agonist” acting on GLP-1, GIP, and glucagon receptors, showing even greater weight loss in early studies.
- Oral GLP-1 medications: Tablets that could replace injections in the future.
- Combination therapies: Targeting multiple pathways for even more effective appetite and metabolism control.
The field of obesity medicine is moving faster than ever before, offering hope to millions living with overweight or obesity worldwide.
Conclusion
Both Wegovy and Mounjaro represent a breakthrough in the treatment of obesity.
- Wegovy has a proven track record, with predictable outcomes and widespread availability.
- Mounjaro offers even greater weight loss potential, thanks to its dual mechanism of action.
The choice between them depends on individual goals, tolerance, and medical history. What is clear, however, is that these treatments are transforming lives and reshaping how we view obesity care.
At Tracey Bell Clinics, we believe in patient-centred care: tailoring treatment to each individual, offering safe prescribing, and supporting every step of the journey. Weight loss is not simply about numbers on the scales — it is about improving health, confidence, and quality of life.
Back to blog